Qimai Guoji Biotechnology

Beijing Gene MiNK Biotechnology Co., Ltd. (also known as Beijing Qimai Yonghua Biotechnology Co., Ltd.) is an innovative biopharmaceutical company focused on the research and development of immune cell-based therapies, specifically NK and CAR-NK cell therapies. Founded in December 2021 by two US-returned scientists, the company has developed a proprietary, serum-free, and feeder-cell-free NK cell expansion platform that overcomes traditional manufacturing bottlenecks, achieving tens of thousands-fold expansion with over 98% purity. Its pipeline includes six novel therapeutic candidates, led by QM103, a BCMA-targeted CAR-NK therapy for relapsed/refractory multiple myeloma, and QM101, an autologous NK cell therapy for advanced solid tumors, both of which have received IND clearances from China's NMPA. The company is backed by Seed, Angel, and Series A funding and collaborates with Porton Advanced as its exclusive CDMO partner.